Showing results (71-80 of 368) with videos related to
Sort By:
Pageof 37
Joint Commission Journal on Quality and Patient Safety|September 26, 2012
Discontinuation of antihyperglycemic therapy after acute myocardial infarction: medical necessity or medical error?Kay O Lovig, Leora Horwitz, Kasia Lipska, et al.International Journal of Stroke : Official Journal of the International Stroke Society|December 4, 2018
Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular diseaseJennifer L Dearborn, Catherine M Viscoli, Silvio E Inzucchi, et al.Diabetes Care|August 21, 2010
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetesJulio Rosenstock, Silvio E Inzucchi, Jochen Seufert, et al.Annals of Internal Medicine|April 20, 2011
Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trialsFaramarz Ismail-Beigi, Etie Moghissi, Margaret Tiktin, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 6, 2011
Adapting to the new consensus guidelines for managing hyperglycemia during critical illness: the updated Yale insulin infusion protocolShilpa Shetty, Silvio E Inzucchi, Philip A Goldberg, et al.Diabetes, Obesity & Metabolism|January 29, 2019
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade laterDarren K McGuire, Nikolaus Marx, Odd Erik Johansen, et al.Diabetes, Obesity & Metabolism|September 24, 2021
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trialJoão Pedro Ferreira, Silvio E Inzucchi, Michaela Mattheus, et al.Journal of Pharmaceutical Policy and Practice|April 16, 2021
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefitsDarren K McGuire, Silvio E Inzucchi, Odd Erik Johansen, et al.Journal of Diabetes and Its Complications|October 18, 2023
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of riskRobert Weingold, Bernard Zinman, Michaela Mattheus, et al.Bone Reports|March 21, 2020
Corrigendum to "Skeletal disease in a father and daughter with a novel monoallelic WNT1 mutation" [Bone Rep. 9 (2018) 154-158]Kathleen Timme, Elizabeth Sanchez Rangel, Qianying Yuan, et al.Pageof 37